$Therapeutic Options in Refractory Diabetic Macular Oedema$

Therapeutic Options in Refractory Diabetic Macular Oedema

Diabetic macular oedema (DMO) results from alterations of several biochemical pathways in diabetic eyes. Centre-involving DMO is an important cause of visual loss in diabetes. Anti-vascular endothelial growth factor agents are now the mainstay of centre-involving DMO treatment. Oedema that does not...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Drugs (New York, N.Y.) N.Y.), 2017-04, Vol.77 (5), p.481-492
Hauptverfasser:	Shah, Sanket U., Maturi, Raj K.
Format:	Artikel
Sprache:	eng
Schlagworte:	Angiogenesis Inhibitors - administration & dosage Angiogenesis Inhibitors - therapeutic use Combined Modality Therapy Corticoids Corticosteroids Current Opinion Cytokines Diabetes Diabetes mellitus Diabetic retinopathy Diabetic Retinopathy - complications Diabetic Retinopathy - drug therapy Diabetic Retinopathy - physiopathology Disease control Edema Endothelium Eye (anatomy) Genetics Humans Hyperglycemia Internal Medicine Kinases Lasers Literature reviews Macular Edema - complications Macular Edema - drug therapy Macular Edema - physiopathology Management Medicine Medicine & Public Health Metabolism Optical Coherence Tomography Oxidative stress Pathogenesis Pathophysiology Pharmacology/Toxicology Pharmacotherapy Precision medicine Proteins Retina Studies Surgery Tomography Vascular endothelial growth factor Visual perception
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!